METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHEA
Provided herein are methods for treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject wherein the composition has minimal drug-drug interactions with at least one other compound concurrently administered to the subject to treat an HIV infection. Also provided are methods for treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject, wherein the composition does not significantly inhibit the activity of at least one other compound concurrently administered to the subject to treat an HIV infection.
1 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising
administering a composition comprising crofelemer to the subject,
wherein the composition has minimal drug-drug interactions with at least one other compound concurrently administered to the subject to treat an HIV infection.
2 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not significantly inhibit the activity of at least one other compound concurrently administered to the subject to treat an HIV infection.
3 . The method of claim 1 , wherein the at least one other compound is an anti-retroviral therapy (ART) compound.
4 . The method of claim 1 , wherein the at least one other compound is selected from the group of: ritonavir, tenofovir, emtricitabine, lamivudine, lopinavir and efavirenz.
5 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises efiravenz, emtricitabine and tenofovir.
6 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises emtricitabine, ritonavir and tenofovir.
7 . The method of claim 6 , wherein the at least one other compound further comprises at least one selected from the group of: lopinavir, atazanavir, fosamprenavir, and darunavir.
8 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises emtricitabine, lopinavir, ritonavir and tenofovir.
9 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises lamivudine, lopinavir and ritonavir.
10 . The method of claim 9 , wherein the at least one other compound further comprises at least one selected from the group of: abacavir and zidovudine.
11 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises lopinavir and ritonavir.
12 . The method of claim 11 , wherein the at least one other compound further comprises at least one selected from the group of: emtricitabine, tenofovir, lamivudine, abacavir, zidovudine and didanosine.
13 . The method of claim 1 , wherein the at least one other compound concurrently administered to the subject comprises: lamivudine and zidovudine.
14 . The method of claim 13 , wherein the at least one other compound further comprises at least one selected from the group of: efiravenz, nelfinavir, ritonavir, lopinavir and abacavir.
15 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not significantly inhibit a CYP enzyme in vivo.
16 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not significantly inhibit the activity of a drug transporter in vivo.
17 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not significantly affect the efficacy of at least one other compound concurrently administered to the subject to treat an HIV infection.
18 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition has negligible permeability as measured by in vitro permeability assays.
19 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition has limited systemic exposure in vivo.
20 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not provoke a significant adverse event in vivo.
21 . The method of claim 20 , wherein the adverse event is at least one selected from the group of: dyspepsia, flatulence, abdominal pain, hemorrhoids, upper respiratory tract infection, and urinary tract infection.
22 . A method of treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject, comprising:
administering a composition comprising crofelemer to the subject,
wherein the composition does not cause deterioration of immune status in the subject.
23 . The method of claim 1 , wherein crofelemer is administered to the subject at a dosage of about 250 mg per day.
24 . The method of claim 1 , wherein crofelemer is administered to the subject at a dosage of about 125 mg two times per day.
25 . The method of claim 1 , wherein the composition is administered to the subject for between about one month and about six months.
26 . The method of claim 1 , wherein the composition is administered to the subject for between about three days and about six months.
27 . The method of claim 1 , wherein the subject experiences an improvement of symptoms on Day 3 after treatment begins.
28 . The method of claim 1 , wherein the composition is administered to the subject for at least about eight days.
29 . The method of claim 1 , wherein the composition is administered to the subject for between about eight days and about 24 weeks.
30 . The method of claim 1 , wherein the composition is administered to the subject for about six months.
31 . The method of claim 1 , wherein the composition is administered to the subject for at least about six months.
32 . The method of claim 1 , wherein the composition is administered to the subject for the duration of the subject's HIV infection.
33 . The method of claim 1 , wherein administration of the composition results in improvement in stool consistency.
34 . The method of claim 1 , wherein administration of the composition results in an improvement in a score for daily stool consistency relative to baseline measurements.
35 . The method of claim 1 , wherein administration of the composition results in alleviation of watery diarrhea.
36 . The method of claim 1 , wherein administration of the composition results in a decrease in the number of bowel movements per day relative to baseline measurements.
37 . The method of claim 1 , wherein administration of the composition results in a decrease in the number of water bowel movements per day relative to baseline measurements.
38 . The method of claim 1 , wherein administration of the composition results in an improvement in the daily abdominal score for pain or discomfort relative to baseline measurements.
39 . The method of claim 1 , wherein administration of the composition results in a decrease in the number of days per week that the subject experiences urgency relative to baseline measurements.
40 . The method of claim 1 , wherein administration of the composition results in a decrease in the number of days per week that the subject experiences fecal incontinence relative to baseline measurements.
41 . The method of claim 1 , wherein the subject has previously been administered protease inhibitors.